Accessibility Menu
Certara logo

Certara(NASDAQ) CERT

Market Cap$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-79%
5 Year-72%
1 Year-24%
1 Month+20%
$8.34
+4.12%
+0.33Today
After hours$8.35+$0.01 (+0.12%)
Certara last closing stock price
MetricPriceDate
Last closeUSD 8.362026-08-19
Certara stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.37%USD 8.012026-08-12
1 month+20.46%USD 6.942026-07-20
3 month+61.7%USD 5.172026-05-21
Year to date-5.11%USD 8.812025-12-31
1 year-24.14%USD 11.022025-08-19
3 year-47.88%USD 16.042023-08-18
5 year-71.73%USD 29.572021-08-20
Since inception-78.97%USD 38.082020-12-11

Certara Financials at a Glance

Market Cap

$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$408.45M

Net Income (TTM)

-$68.40M

EPS (TTM)

-$0.02

P/E Ratio

-494.67

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Price

$8.34

Volume

1,044

Open

$8.11

Previous Close

$8.36

Daily Range

$8.08 - $8.37

52-Week Range

$4.45 - $13.88

Estimated Earnings Date

Nov 5, 2026

CERT News

f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png

Certara Stock Fell 23% After Earnings and This Fund Bought Up $3 Million Anyway

Jonathan PoncianoJan 5, 2026
Foolcom-Featured.png

Certara (CERT) Q2 Revenue Jumps 12%

Motley Fool Markets TeamAug 6, 2025
scientist sterilizing test tubes lab science

Why Certara's Shares Rose 37.7% This Week

James HalleyNov 11, 2022

CERT: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Certara

Certara, Inc. helps drug companies use computer models to test new medicines before they reach people. This technology, called biosimulation, reduces the time and cost needed to get treatments approved. The company supports scientists in making better decisions about how drugs will behave in patients.

The Virtual Testing Ground

  • Biosimulation Software: Mathematical models predicting how medicines behave in biological systems; generated $48.8 million in the quarter ended June 30, 2026.
  • Technology-Enabled Services: Expert-led consulting applying modeling to specific drug development projects; generated $44.5 million in the quarter ended June 30, 2026.
  • Data Solutions: Software for collecting and standardizing the scientific information needed for modeling and analytics.

Shifting the Business Mix

  • Completed the sale of the global medical writing and regulatory services business on May 8, 2026.
  • Received $69.4 million in cash from the sale, with an additional $15.0 million held in escrow.
  • Integrated machine learning to automate biosimulation and increase the speed of predicting drug outcomes.
  • Repurchased 9,009,459 shares of common stock for $57.4 million during the first half of 2026.

A Trusted Regulatory Partner

Regulators at 20 global agencies, such as the FDA and Japan's PMDA, utilize the company's software to review new medicines. Since 2014, clients using these biosimulation tools have earned 90% or more of all new drug approvals by the FDA.

Monitoring the Financial Results

  • Total revenues reached $93.3 million for the three months ended June 30, 2026, up 1% year over year.
  • Net loss from continuing operations was $6.1 million for the three months ended June 30, 2026.
  • Software revenue grew 6% to $98.5 million for the six months ended June 30, 2026.
  • Cash and cash equivalents totaled $184.1 million as of June 30, 2026.

Bottom Line

Certara has evolved from a specialized consulting firm to a technology-driven leader in biosimulation. Its focus on divesting noncore services while integrating artificial intelligence supports its long-term strategy for biopharmaceutical innovation.

AI Generated • Aug 4, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

1,576

CEO

Jon Resnick, MBA

Website

www.certara.com

Headquarters

Radnor, PA 19087, US

CERT Financials

Key Financial Metrics (TTM)

Gross Margin

58.33%

Operating Margin

1.86%

Net Income Margin

-16.75%

Return on Equity

-6.66%

Return on Capital

1.96%

Return on Assets

-4.89%

Earnings Yield

-0.20%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

152.54M

Volume

1.04K

Avg. Volume

4.24M

Financials (TTM)

Gross Profit

$238.24M

Operating Income

$7.60M

EBITDA

$83.29M

Operating Cash Flow

$82.86M

Capital Expenditure

-$21.22M

Free Cash Flow

$61.64M

Cash & ST Invst.

$184.14M

Total Debt

$291.84M

Certara Performance Analysis

Certara annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 335,644,00017.3%
20232023-12-31USD 354,337,0005.6%
20242024-12-31USD 385,148,0008.7%
20252025-12-31USD 418,838,0008.7%
Certara sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-300.0%
Q42025-12-31-0.9%
Q12026-03-313.2%
Q22026-06-30-12.8%
Certara annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.09N/A
20232023-12-31USD -0.35N/A
20242024-12-31USD -0.08-78.4%
20252025-12-31USD -0.01-86.8%
Certara sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30177.9%
Q42025-12-31-492.6%
Q12026-03-31-49.1%
Q22026-06-30-547.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$93.27M

-10.8%

Gross Profit

$58.15M

-8.9%

Gross Margin

62.34%

N/A

Market Cap

$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$824.86K

N/A

Employees

1,546

N/A

Net Income

-$55.27M

-2708.4%

EBITDA

$11.88M

-60.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$184.14M

+13.5%

Total Debt

$291.84M

-5.2%

Accounts Receivable

$113.90M

+7.1%

Inventory

$0.00

N/A

Long Term Debt

$288.88M

-3.9%

Short Term Debt

$2.96M

-59.5%

Return on Assets

-4.89%

N/A

Return on Invested Capital

0.59%

N/A

Free Cash Flow

$9.42M

-13.5%

Operating Cash Flow

$10.04M

-43.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SDGRSchrödinger, Inc.
$19.85+12.34%
QDELQuidelOrtho Corporation
$13.80+2.76%
OMCLOmnicell, Inc.
$36.43+1.28%
PGNYProgyny, Inc.
$25.53-0.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBSWebster Financial
$77.57-0.01%
IBITiShares Bitcoin Trust
$38.78+0.06%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.05+0.06%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$120.74-0.06%

Questions About CERT

What is the current price of Certara?

Certara is trading at $8.36 per share.

What is the 52-week range for Certara?

Over the past 52 weeks, Certara has traded between $4.45 and $13.88.

How much debt does Certara have?

As of the most recent reporting period, Certara reported total debt of $301.95M.

How much cash does Certara have on hand?

Certara reported $184.14M in cash and cash equivalents in its most recent financial results.

What is Certara’s dividend yield?

Certara does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services